# Oman Diabetes Devices Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2026-2031 --- ## Market Overview # CHAPTER 1 - Market Overview The Oman Diabetes Devices Market operates through a recurring-consumables model spanning glucose meters, test strips, continuous glucose monitoring sensors, insulin pens, needles and pumps. Oman’s 2025 STEPS survey recorded raised fasting glucose or diabetes medication use in 13.4% of adults, creating a substantial treated and monitored population whose device demand depends on testing frequency, insulin intensity and reimbursement access. Muscat is the commercial and clinical hub because tertiary hospitals, specialist clinics, private pharmacies and national distributors are concentrated around the capital. The Ministry of Health’s 2025 diabetic-retinopathy program placed retinal imaging equipment in 25 healthcare institutions during its first phase, demonstrating how advanced diabetes technology is deployed through centralized procurement before scaling across other governorates. Market access is increasingly shaped by risk-based medical-device registration. The Drug Safety Center specifies a 60-working-day registration service and requires local establishment approval, manufacturer registration and a local agency certificate. Registration fees are differentiated by device class, increasing compliance costs for connected insulin-delivery and higher-risk systems while improving traceability, product vigilance and procurement confidence. Oman remains import-dependent for branded diabetes devices, so distributor capability, inventory planning and after-sales support materially affect market performance. At the same time, more than 6,500 new diabetes cases are recorded annually and noncommunicable diseases account for 80% of deaths, supporting a durable transition toward preventive monitoring, remote care and earlier technology adoption. ## KPIs at a Glance * Market Value: USD 68 million (2025) * Dominant Region: Muscat Governorate * Dominant Segment: Continuous Glucose Monitoring Systems (fastest growing) * Total Number of Players: 24 ## Future Outlook The Oman Diabetes Devices Market is projected to increase from USD 68 million in 2025 to USD 80 million by 2031. Historical growth averaged 3.59% during 2020-2025, supported by expanding diagnosed-patient coverage, greater use of self-monitoring consumables and wider availability of insulin delivery devices. Forecast growth moderates to 2.75% because conventional glucometers and pen-based delivery products are mature, while public procurement remains price sensitive. The market nevertheless retains a recurring revenue profile because test strips, lancets, CGM sensors, infusion sets and pen needles require frequent replacement across homecare and institutional settings. Growth through 2031 will increasingly come from mix rather than basic device penetration. Continuous glucose monitoring, flash monitoring and connected insulin-delivery systems are expected to capture a larger share of incremental revenue as clinicians prioritize better glycemic control and remote review. Oman’s 2025 survey showed only 26.0% of people with raised glucose had fasting blood glucose below 7.0 mmol/L, indicating a large outcomes gap. Suppliers that combine devices with onboarding, clinical education, digital dashboards and reliable replenishment will be better positioned than hardware-only vendors, particularly in specialist clinics and coordinated public-health programs. --- | | | | --- | --- | | **2.75%** Forecast CAGR | **$80 Mn** 2031 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2026-2031** | Historical CAGR **3.59%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** Sultanate of Oman * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2026-2031 * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Distribution Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn ### Segmentation Data Tree * Product Type + Self-Monitoring Blood Glucose Devices - Blood Glucose Meters - Test Strips and Lancets + Continuous Glucose Monitoring Systems - Disposable Sensors - Transmitters and Readers + Insulin Delivery Devices - Insulin Pens and Needles - Pumps, Reservoirs and Infusion Sets + Connected Diabetes Management Devices - Smart Pens and Dose Trackers - Connected Meters and Software * Care Setting + Homecare - Self-Managed Adults - Caregiver-Assisted Patients + Hospitals - Inpatient Diabetes Care - Hospital Outpatient Clinics + Specialized Diabetes Clinics - Endocrinology Clinics - Diabetes Education Centers + Diagnostic and Primary Care Centers - Primary Health Centers - Private Diagnostic Networks * End User + Adults with Type 2 Diabetes - Insulin-Treated Adults - Non-Insulin Monitoring Users + Adults with Type 1 Diabetes - Multiple Daily Injection Users - Pump Therapy Users + Pediatric Patients - Children under 12 - Adolescents 12-17 + Caregivers and Clinicians - Family Caregivers - Diabetes Care Teams * Disease Area + Type 2 Diabetes - Insulin-Dependent Type 2 - Oral-Therapy Monitoring + Type 1 Diabetes - Adult Type 1 - Pediatric Type 1 + Gestational Diabetes - Antenatal Screening - Pregnancy Glucose Management + Prediabetes and High-Risk Monitoring - Impaired Fasting Glucose - Obesity-Linked Risk Monitoring * Distribution Channel + Hospital Procurement - Ministry Tenders - Private Hospital Purchasing + Retail Pharmacies - National Pharmacy Chains - Independent Pharmacies + Specialist Medical Distributors - Authorized Brand Distributors - Clinical Equipment Suppliers + Digital Pharmacy and Direct-to-Consumer - Online Pharmacy Platforms - Subscription Replenishment * Technology + Conventional Electrochemical Monitoring - Capillary Blood Testing - Enzyme-Based Test Strips + Flash Glucose Monitoring - Scan-Based Sensors - Near-Field Communication Readers + Real-Time Continuous Glucose Monitoring - Smartphone-Connected CGM - Alarm-Enabled CGM + Automated Insulin Delivery - Hybrid Closed-Loop Systems - Patch Pump Platforms * Geography + Muscat - Central Muscat - Greater Muscat Corridor + North Al Batinah - Sohar Cluster - Coastal Health Centers + Dhofar - Salalah Cluster - Peripheral Dhofar + Interior and Other Governorates - Ad Dakhiliyah and Al Dhahirah - Sharqiyah, Buraimi and Musandam --- ## Market Trajectory # Oman Diabetes Devices Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2026-2031 **Geography:** Oman | **Outlook Period:** 2026-2031 The Oman Diabetes Devices Market reached USD 68 million in 2025, supported by a 13.4% adult diabetes burden, expanding home-based monitoring and public-sector chronic care procurement. The market is strategically relevant because recurring consumables, continuous glucose monitoring sensors and connected insulin-delivery platforms are shifting value from one-time hardware toward higher-retention patient ecosystems. ## Report Metadata Summary | | | | --- | --- | | **Base Year** | 2025 | | **CAGR for Past 5 Years** | 3.59% | | **Historical Period** | 2020-2025 | | **Forecast Period** | 2026-2031 | | **Forecast Period CAGR** | 2.75% | # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. | Year | Market Size (USD Mn) | Period | | --- | --- | --- | | 2020 | 57 | Historical | | 2021 | 59 | Historical | | 2022 | 61 | Historical | | 2023 | 63 | Historical | | 2024 | 66 | Historical | | 2025 | 68 | Base Year | | 2026F | 70 | Forecast | | 2027F | 72 | Forecast | | 2028F | 74 | Forecast | | 2029F | 76 | Forecast | | 2030F | 78 | Forecast | | 2031F | 80 | Forecast | | Year | YoY Growth Rate (%) | | --- | --- | | 2021 | 3.51 | | 2022 | 3.39 | | 2023 | 3.28 | | 2024 | 4.76 | | 2025 | 3.03 | | 2026F | 2.94 | | 2027F | 2.86 | | 2028F | 2.78 | | 2029F | 2.70 | | 2030F | 2.63 | | 2031F | 2.56 | | Year | Market Value Growth (%) | Device User Volume Growth (%) | Value-Volume Gap (pp) | | --- | --- | --- | --- | | 2020 | - | - | - | | 2021 | 3.51 | 3.78 | -0.27 | | 2022 | 3.39 | 4.05 | -0.66 | | 2023 | 3.28 | 4.28 | -1.00 | | 2024 | 4.76 | 5.22 | -0.46 | | 2025 | 3.03 | 5.67 | -2.64 | | 2026 | 2.94 | 5.37 | -2.43 | | 2027 | 2.86 | 5.41 | -2.55 | | 2028 | 2.78 | 5.44 | -2.66 | | 2029 | 2.70 | 5.44 | -2.74 | | 2030 | 2.63 | 5.71 | -3.08 | ### Historical Market Performance (2020-2025) The market expanded from USD 57 million in 2020 to USD 68 million in 2025. The strongest annual increase occurred in 2024 at 4.76%, when public-health normalization, distributor restocking and stronger uptake of sensor-based monitoring lifted revenue. Growth slowed to 3.03% in 2025 as conventional self-monitoring products faced tender-price pressure. Device-user volume rose faster than value throughout the period, indicating broader access but declining average spend per patient in mature glucometer and pen-needle categories. ### Forecast Market Outlook (2026-2031) Revenue is forecast to reach USD 80 million by 2031, representing a 2.75% CAGR from 2025. The terminal growth rate remains moderate because basic monitoring and injection devices are established, but product mix improves as CGM sensors, smart pens and automated delivery platforms gain clinical relevance. User-equivalent volume is projected to rise above 5% annually, outpacing value growth as lower-cost sensors, competitive procurement and bundled care programs extend access beyond intensive insulin users. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Oman Diabetes Devices Market combines a mature base of self-monitoring and injection consumables with a faster-moving digital layer. For CEOs and investors, the critical question is whether suppliers can convert expanding patient coverage into recurring sensor, software and replenishment revenue without losing margin to public-sector price compression. | Year | Market Size (USD Mn) | YoY Growth (%) | Active Device Users (000) | CGM Revenue Share (%) | Homecare Revenue Share (%) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 57 | - | 238 | 5.0 | 49 | Historical | | 2021 | 59 | 3.51 | 247 | 5.5 | 50 | Historical | | 2022 | 61 | 3.39 | 257 | 6.2 | 51 | Historical | | 2023 | 63 | 3.28 | 268 | 7.1 | 52 | Historical | | 2024 | 66 | 4.76 | 282 | 8.4 | 54 | Historical | | 2025 | 68 | 3.03 | 298 | 10.0 | 56 | Base Year | | 2026 | 70 | 2.94 | 314 | 11.5 | 57 | Forecast and Latest Operating KPIs | | 2027 | 72 | 2.86 | 331 | 13.0 | 58 | Forecast and Industry Outlook | | 2028 | 74 | 2.78 | 349 | 14.5 | 59 | Forecast and Industry Outlook | | 2029 | 76 | 2.70 | 368 | 16.0 | 60 | Forecast and Industry Outlook | | 2030 | 78 | 2.63 | 389 | 17.5 | 61 | Forecast and Industry Outlook | | 2031 | 80 | 2.56 | 411 | 19.0 | 62 | Forecast and Industry Outlook | **KPI 1, Active Device Users:** **298,000 users, 2025, Oman**. User growth exceeds revenue growth, so retention, consumable adherence and service attachment are more important than hardware shipment volume. Raised fasting glucose or diabetes medication use affected 13.4% of adults in the 2025 survey. **KPI 2, CGM Revenue Share:** **10.0%, 2025, Oman**. Sensor-based monitoring provides the clearest premium growth pool, but adoption depends on clinician education and payer support. Only 55.6% of people with raised glucose were previously diagnosed, leaving substantial scope for screening-linked device demand. **KPI 3, Homecare Revenue Share:** **56%, 2025, Oman**. Homecare shifts purchasing toward pharmacy, distributor and subscription channels, increasing the value of reliable replenishment. Just 26.0% of people with raised glucose had fasting glucose below 7.0 mmol/L, reinforcing demand for more continuous feedback. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Product Type | **Fastest Growing Segment:** Technology | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Self-Monitoring Blood Glucose Devices; Continuous Glucose Monitoring Systems; Insulin Delivery Devices; Connected Diabetes Management Devices | | 2 | Care Setting | Homecare; Hospitals; Specialized Diabetes Clinics; Diagnostic and Primary Care Centers | | 3 | End User | Adults with Type 2 Diabetes; Adults with Type 1 Diabetes; Pediatric Patients; Caregivers and Clinicians | | 4 | Disease Area | Type 2 Diabetes; Type 1 Diabetes; Gestational Diabetes; Prediabetes and High-Risk Monitoring | | 5 | Distribution Channel | Hospital Procurement; Retail Pharmacies; Specialist Medical Distributors; Digital Pharmacy and Direct-to-Consumer | | 6 | Technology | Conventional Electrochemical Monitoring; Flash Glucose Monitoring; Real-Time Continuous Glucose Monitoring; Automated Insulin Delivery | | 7 | Geography | Muscat; North Al Batinah; Dhofar; Interior and Other Governorates | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns. **Product Type** - Product economics are dominated by recurring insulin-delivery and glucose-monitoring consumables rather than durable hardware. Insulin Delivery Devices retain the largest revenue pool because pens, needles, syringes and pump consumables require repeated purchase, while Continuous Glucose Monitoring Systems generate the strongest mix uplift through sensor replacement and connected clinical workflows. **Technology** - Technology is the fastest-growing dimension as care moves from episodic finger-stick testing toward real-time, smartphone-connected and increasingly automated management. Real-Time Continuous Glucose Monitoring is the leading growth sub-segment because it supports alerts, remote review and better treatment adjustment, while Automated Insulin Delivery remains smaller but strategically important for high-intensity users. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis Oman ranks below Saudi Arabia, the UAE and Kuwait in diabetes-device revenue, but it remains a strategically relevant GCC market because diabetes prevalence is high and specialist access is improving. Its slower growth profile reflects mature public procurement and lower advanced-device coverage, creating a focused opportunity for affordable CGM and connected-care models. ### KPI Summary * Focus Country Ranking: **4th** * Focus Country Market Size: **USD 68 Mn** * Oman CAGR (2026-2031): **2.75%** | Country | Market Size (USD Mn, 2025) | CAGR (%) | Adult Diabetes Prevalence (%) | Advanced Device Coverage among Diagnosed Patients (%) | | --- | --- | --- | --- | --- | | Saudi Arabia | 425 | 7.8 | 20.4 | 37 | | United Arab Emirates | 175 | 8.1 | 16.4 | 42 | | Kuwait | 82 | 6.9 | 24.9 | 35 | | Oman | 68 | 2.75 | 13.4 | 29 | | Qatar | 61 | 7.4 | 16.5 | 39 | ### Market Position Oman ranks fourth among selected GCC peers with USD 68 million in 2025 revenue, supported by a sizeable monitored population but constrained by smaller national scale than Saudi Arabia and the UAE. ### Growth Advantage Oman’s 2.75% forecast CAGR trails the UAE at 8.1% and Saudi Arabia at 7.8%, positioning it as a selective value market rather than a regional volume-growth leader. ### Competitive Strengths Oman combines a 13.4% adult diabetes burden, 25 first-phase AI retinopathy screening sites and formal 60-working-day device registration, supporting structured technology deployment and traceable market access. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Oman Diabetes Devices Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### Expanding Diagnosed and Treatable Diabetes Population A broad chronic-care base is sustained by **13.4% adult raised-glucose prevalence (2025, Oman)**, supporting recurring monitoring and delivery demand. * More than **6,500 new diabetes cases annually (2025, Oman)** expand the addressable pool for meters, strips, pens and education services, benefiting distributors with broad primary-care coverage. * Only **55.6% prior diagnosis among people with raised glucose (2025, Oman)** indicates a significant detection gap, creating demand for screening-linked device pathways and pharmacy-based onboarding. * A **64.7% overweight prevalence (2025, Oman)** reinforces long-term Type 2 diabetes risk, increasing the economic value of scalable home monitoring and early-intervention programs. ### Shift Toward Continuous and Connected Monitoring Clinical outcomes gaps, including **26.0% fasting-glucose control (2025, Oman)**, support migration toward real-time feedback and remote review. * CGM reduces dependence on episodic finger-stick testing, and Oman’s **53.2% treatment rate among people with raised glucose (2025, Oman)** provides a defined cohort for higher-intensity monitoring. * The national diabetic-retinopathy project deployed imaging technology across **25 healthcare institutions in phase one (2025, Oman)**, demonstrating policy willingness to integrate advanced diabetes technologies into public pathways. * The Oman blood-glucose-monitoring segment is projected to grow at **9.60% CAGR during 2025-2030 (Oman)**, favoring sensor manufacturers, connected-device platforms and specialist distributors. ### Formalization of Medical-Device Market Access Risk-based registration with a **60-working-day completion period (2025, Oman)** improves traceability and creates clearer entry pathways for compliant suppliers. * Registration requires **local establishment and manufacturer approval (2025, Oman)**, increasing the strategic value of capable local partners that can manage vigilance, documentation and tender participation. * Class-based fees of **100 for A-B and 200 for C-D devices (2025, Oman)** establish a predictable compliance cost structure while raising barriers for unsupported low-volume brands. * Ministerial Decree **113/2020 (Oman)** underpins manufacturer and device registration, strengthening procurement confidence for connected meters, pumps and higher-risk systems. --- ## Market Challenges ### Affordability and Reimbursement Constraints Advanced-device adoption remains limited because the market grows at only **2.75% CAGR during 2026-2031 (Oman)** despite a substantial disease burden. * CGM and pump economics require recurring sensor, reservoir and infusion-set spending, while basic devices dominate price-sensitive tenders, compressing supplier margins and slowing premium conversion across public care. **USD 68 million market value (2025, Oman)**. [kenresearch.com](https://www.kenresearch.com/oman-diabetes-devices-market) * Only **53.2% of people with raised glucose were currently treated (2025, Oman)**, showing that clinical access gaps persist before premium-device affordability is considered. * Suppliers must balance affordability with service costs because device education, calibration support and replenishment logistics increase total delivered cost beyond hardware pricing. Diabetes represented **24.2% of Oman health expenditure in the 2019 NCD investment case**. ### Imported Supply and Distributor Dependence The sector is structurally import-led, with **more than 90% of branded device value supplied internationally (2025, Oman estimate)**, increasing channel and inventory risk. [kenresearch.com](https://www.kenresearch.com/oman-diabetes-devices-market) * Authorized distributors carry registration, customs, tender and service obligations, so weak partner execution can delay launches and reduce continuity for consumables with fixed replacement cycles. **60 working days registration period (2025, Oman)**. * Small national order volumes reduce bargaining power relative to larger GCC markets, increasing exposure to regional allocation decisions and minimum-order quantities. Oman ranks **4th among selected GCC peers (2025)**. * Product continuity is operationally critical because test strips, CGM sensors and infusion sets are not always interchangeable. The modeled active base reaches **298,000 device users (2025, Oman)**, magnifying the impact of stock-outs. ### Diagnosis, Adherence and Outcomes Gaps Device availability does not automatically improve outcomes, as only **26.0% achieved fasting glucose below 7.0 mmol/L (2025, Oman)**. * A prior-diagnosis rate of **55.6% among people with raised glucose (2025, Oman)** limits the addressable monitored population and delays intervention until complications emerge. * Physical inactivity affects **27.9% of adults (2025, Oman)**, so device-led management must be integrated with behavioral support rather than treated as a standalone technology purchase. * Clinical teams need interoperable data and patient training to convert measurements into treatment changes. The national survey mobilized **165 field teams (2025, Oman)**, illustrating the scale of human capability required for population-level chronic care. --- ## Market Opportunities ### Affordable CGM Subscription Models CGM can address the control gap while building recurring revenue from **sensor replacement every 10-15 days (2025, global technology benchmark)**. * Monetizable angle: monthly sensor bundles, app access and clinical review can raise lifetime value while reducing upfront cost barriers for insulin-treated users. **9.60% monitoring CAGR (2025-2030, Oman)**. * Who benefits: specialist clinics, pharmacies and distributors can earn replenishment and service revenue from a diagnosed cohort representing **55.6% of raised-glucose adults (2025, Oman)**. * What must change: reimbursement criteria and clinician protocols must prioritize high-risk patients, supported by adherence evidence and outcomes tracking against the current **26.0% control rate (2025, Oman)**. ### Primary-Care Screening to Device Conversion Screening-led acquisition can unlock an underdiagnosed pool because only **55.6% were previously diagnosed (2025, Oman)** among adults with raised glucose. * Monetizable angle: bundled screening, starter meters, test strips and remote coaching can create lower-cost entry products with repeat consumable revenue across primary-care networks. **13.4% raised-glucose prevalence (2025, Oman)**. * Who benefits: local distributors and pharmacy chains gain customer acquisition at diagnosis, while public providers reduce late-stage complication costs associated with **more than 6,500 new cases annually (2025, Oman)**. * What must change: screening results need referral, device initiation and replenishment workflows, building on the national survey’s **10,174 adult participants and 83% response rate (2025, Oman)**. ### Connected Care and Clinical Data Services Remote dashboards can convert devices into care infrastructure as homecare reaches **56% of market revenue (2025, Oman estimate)**. [kenresearch.com](https://www.kenresearch.com/oman-diabetes-devices-market) * Monetizable angle: providers can charge for remote review, adherence alerts and risk stratification, attaching software revenue to a modeled **298,000 active device users (2025, Oman)**. [kenresearch.com](https://www.kenresearch.com/oman-diabetes-devices-market) * Who benefits: hospitals, specialist clinics and device vendors gain earlier visibility into glucose excursions, while patients reduce unnecessary visits across a system serving **5.049 million people (2023, Oman)**. * What must change: interoperability, consent and cybersecurity standards must connect meters, CGM and insulin platforms with national digital-health systems, building on **25 AI screening institutions (2025, Oman)**. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview The market is moderately concentrated around multinational brands with strong consumable portfolios, local regulatory partners and tender access. Entry barriers include device registration, clinical education, replenishment continuity and the service capability required for connected monitoring and insulin-delivery platforms. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | Abbott Diabetes Care | - | Abbott Park, Illinois, United States | 1888 | FreeStyle glucose monitoring and CGM systems | | Roche Diabetes Care | - | Basel, Switzerland | 1896 | Accu-Chek meters, strips and connected diabetes management | | LifeScan | - | Malvern, Pennsylvania, United States | 1981 | OneTouch blood glucose meters and test strips | | Medtronic plc | - | Dublin, Ireland | 1949 | Insulin pumps, CGM and automated insulin delivery | | Ascensia Diabetes Care | - | Basel, Switzerland | 2016 | Contour meters, strips and digital glucose management | | Dexcom, Inc. | - | San Diego, California, United States | 1999 | Real-time continuous glucose monitoring systems | | Insulet Corporation | - | Acton, Massachusetts, United States | 2000 | Tubeless insulin pump and automated delivery platforms | | Ypsomed Holding AG | - | Burgdorf, Switzerland | 1984 | Injection systems, insulin pumps and smart delivery | | ARKRAY, Inc. | - | Kyoto, Japan | 1960 | Blood glucose meters, strips and clinical analyzers | | Becton, Dickinson and Company | - | Franklin Lakes, New Jersey, United States | 1897 | Pen needles, syringes and injection accessories | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * Installed Patient Base * Sensor Replacement Adherence * Oman Diabetes Device Revenue Growth * Gross Margin ### Analysis Covered * **Market Share Analysis:** Compares supplier positions across monitoring, delivery and connected device categories. * **Cross Comparison Matrix:** Benchmarks patient reach, adherence, growth and margin performance consistently. * **SWOT Analysis:** Assesses portfolio strengths, channel dependencies, technology gaps and threats. * **Pricing Strategy Analysis:** Evaluates tender pricing, retail premiums and subscription economics by segment. * **Company Profiles:** Reviews Oman relevance, product focus, headquarters and establishment history. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, recurring revenue, reimbursement exposure, margin durability * **Corporates:** portfolio mix, tender access, channel productivity, retention * **Government:** diagnosis coverage, glycemic control, compliance, care equity * **Operators:** replenishment, device uptime, training, data interoperability * **Financial institutions:** working capital, inventory risk, demand stability, covenants ### What You'll Gain * Market sizing and trajectory * Policy and compliance mapping * Patient access indicators * Segment economics and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Reviewed Oman diabetes prevalence indicators * Mapped device registration and vigilance * Benchmarked glucose-monitoring product economics * Assessed public procurement and channels #### Primary Research * Interviewed consultant endocrinologists and diabetologists * Engaged diabetes nurse educators * Consulted medical-device distribution directors * Surveyed pharmacy category managers #### Validation and Triangulation * Validated findings across 284 respondents * Reconciled patient and shipment estimates * Cross-checked tender and retail pricing * Tested replacement-cycle and adherence assumptions ### Phase 2: Market Size Estimation #### Top-Down Assessment * Adult diabetes population and diagnosis coverage * Breakdown by homecare, hospitals and clinics * National health and regulatory datasets #### Bottom-Up Modeling * Supplier shipments by device category * Sensor, strip and needle pricing * Active users multiplied by annual spend #### Forecasting and Scenario Analysis * Diabetes incidence, access and technology mix * Reimbursement, registration and tender-price scenarios * Baseline, optimistic and constrained projections through 2031 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the Oman Diabetes Devices Market value chain from international manufacturers and authorized importers to clinical channels, pharmacies and home users. * Device Manufacturers and Importers * Hospitals and Diabetes Clinics * Pharmacies and Medical Distributors * Homecare Users and Caregivers #### Sample Size A total of 284 respondents were engaged across market segments to ensure robust coverage of purchasing, prescribing, distribution and usage behavior. * Device Manufacturers and Importers - 64 respondents (Country Manager, Regulatory Affairs Manager) * Hospitals and Diabetes Clinics - 78 respondents (Consultant Endocrinologist, Diabetes Nurse Educator) * Pharmacies and Medical Distributors - 72 respondents (Category Manager, Medical Sales Director) * Homecare Users and Caregivers - 70 respondents (Insulin-Treated Patient, Family Caregiver) #### Validation and Triangulation Validation compared commercial, clinical and patient evidence across device categories and channel stages within the Oman Diabetes Devices Market. * Cross-checked prescribed use against purchase frequency * Reconciled manufacturer shipments with channel sell-through * Compared operational and strategic respondent perspectives * Tested consumable cycles against patient adherence --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: How large is the Oman Diabetes Devices Market in the base year? **A:** The Oman Diabetes Devices Market is worth USD 68 million in 2025. The estimate covers self-monitoring blood glucose devices, continuous glucose monitoring systems, insulin-delivery devices and connected diabetes-management devices sold for use in hospitals, clinics, pharmacies and homecare. Demand is supported by a 13.4% adult prevalence of raised fasting glucose or diabetes medication use, while recurring strips, sensors, needles and infusion supplies create a durable replacement cycle. Public procurement remains important, but homecare and pharmacy channels increasingly shape product choice and replenishment. **Data used:** USD 68 million market value in 2025; 13.4% adult raised-glucose prevalence in 2025 **So what:** Suppliers should prioritize recurring consumables and patient-retention models rather than relying on durable device placements alone. #### Q: What is the forecast value and growth rate through 2031? **A:** The market is projected to reach USD 80 million by 2031, expanding at a 2.75% CAGR from 2025. Growth is moderate at the total-market level because conventional meters, test strips, syringes and insulin pens are mature and exposed to procurement pressure. The faster-moving revenue pool is continuous glucose monitoring, connected meters, smart pens and automated insulin delivery. These categories are expected to gain mix as clinicians pursue better control, remote review and reduced treatment friction for insulin-intensive patients. **Data used:** USD 80 million forecast value in 2031; 2.75% CAGR during 2025-2031 **So what:** Investment cases should separate low-growth conventional consumables from faster sensor and connected-care profit pools. #### Q: Where will the market's profit pool shift over the forecast period? **A:** Profit pools will shift toward continuous glucose monitoring sensors, software-enabled monitoring and integrated insulin-delivery ecosystems. Conventional meters create installed-base access, but test strips face tender and retail price competition. CGM sensors generate frequent replacement revenue, while connected platforms can attach onboarding, adherence support and clinician-review services. Homecare revenue is expected to rise as a share of the market, making pharmacy fulfillment, direct-to-consumer replenishment and subscription models strategically more valuable than standalone institutional hardware sales. **Data used:** CGM revenue share rises from 10.0% in 2025 to 19.0% in 2031; homecare share rises from 56% to 62% **So what:** Companies should build service, data and replenishment capabilities around sensors and connected delivery rather than compete only on unit price. #### Q: What is the most important constraint on market expansion? **A:** The largest constraint is the affordability and reimbursement gap for advanced devices. Oman has a sizeable disease burden, but only 53.2% of people with raised glucose were currently treated in the 2025 STEPS survey, and only 26.0% achieved fasting glucose below 7.0 mmol/L. Premium systems require recurring sensor, infusion-set or pump consumable expenditure, which can exceed the budget available through conventional public procurement. Imported supply and distributor dependence further increase landed cost and continuity risk. **Data used:** 53.2% treatment rate in 2025; 26.0% fasting-glucose control rate in 2025 **So what:** Vendors need tiered pricing, evidence-based reimbursement proposals and lower-cost patient support pathways. #### Q: How does Oman compare with neighboring GCC diabetes-device markets? **A:** Oman ranks fourth among the selected peer markets of Saudi Arabia, the UAE, Kuwait, Oman and Qatar by 2025 revenue. Its USD 68 million market is smaller than Saudi Arabia, the UAE and Kuwait, but larger than Qatar in the modeled comparison. Oman’s 2.75% forecast CAGR trails the faster GCC average, reflecting smaller population scale and a more mature conventional-device base. The opportunity is therefore selective: suppliers should focus on high-risk cohorts, specialist clinics and cost-effective connected monitoring rather than assume broad premium adoption. **Data used:** 4th peer-market ranking in 2025; 2.75% Oman CAGR during 2026-2031 **So what:** Regional strategies should treat Oman as a focused clinical-access market, not a simple extension of Saudi or UAE volume models. #### Q: Which demand factor has the strongest long-term impact? **A:** The strongest structural driver is the combination of diabetes incidence, underdiagnosis and obesity-linked risk. More than 6,500 new diabetes cases are recorded annually, while 64.7% of adults were overweight in the 2025 STEPS survey. Only 55.6% of people with raised glucose had been previously diagnosed, leaving a substantial pool that can enter monitoring pathways through screening and primary care. This supports sustained demand for starter meters, strips, connected monitoring and eventually higher-intensity devices as treatment escalates. **Data used:** More than 6,500 new cases annually in 2025; 64.7% adult overweight prevalence in 2025 **So what:** The highest-return growth programs will link screening directly to device initiation, education and replenishment. --- ## Table of Contents # CHAPTER 14 - Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases, Market Assessment, Go-To-Market Strategy, and Survey, delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Oman Diabetes Devices Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Oman Diabetes Devices Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Oman Diabetes Devices Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Expanding Diagnosed and Treatable Diabetes Population ##### 3.1.2 Shift Toward Continuous and Connected Monitoring ##### 3.1.3 Formalization of Medical-Device Market Access #### 3.2 Market Challenges ##### 3.2.1 Affordability and Reimbursement Constraints ##### 3.2.2 Imported Supply and Distributor Dependence ##### 3.2.3 Diagnosis, Adherence and Outcomes Gaps #### 3.3 Market Opportunities ##### 3.3.1 Affordable CGM Subscription Models ##### 3.3.2 Primary-Care Screening to Device Conversion ##### 3.3.3 Connected Care and Clinical Data Services #### 3.4 Market Trends ##### 3.4.1 Recurring Sensor Revenue Expansion ##### 3.4.2 Homecare Replenishment Growth ##### 3.4.3 Smartphone-Connected Glucose Monitoring ##### 3.4.4 Automated Insulin Delivery Adoption #### 3.5 Government Regulation ##### 3.5.1 Risk-Based Medical-Device Registration ##### 3.5.2 Local Agency and Establishment Approval ##### 3.5.3 Manufacturer Registration Requirements ##### 3.5.4 Medical-Device Vigilance and Traceability ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Oman Diabetes Devices Market Historical Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Oman Diabetes Devices Market Segmentation #### 8.1 Product Type ##### 8.1.1 Self-Monitoring Blood Glucose Devices ##### 8.1.2 Continuous Glucose Monitoring Systems ##### 8.1.3 Insulin Delivery Devices ##### 8.1.4 Connected Diabetes Management Devices #### 8.2 Care Setting ##### 8.2.1 Homecare ##### 8.2.2 Hospitals ##### 8.2.3 Specialized Diabetes Clinics ##### 8.2.4 Diagnostic and Primary Care Centers #### 8.3 End User ##### 8.3.1 Adults with Type 2 Diabetes ##### 8.3.2 Adults with Type 1 Diabetes ##### 8.3.3 Pediatric Patients ##### 8.3.4 Caregivers and Clinicians #### 8.4 Disease Area ##### 8.4.1 Type 2 Diabetes ##### 8.4.2 Type 1 Diabetes ##### 8.4.3 Gestational Diabetes ##### 8.4.4 Prediabetes and High-Risk Monitoring #### 8.5 Distribution Channel ##### 8.5.1 Hospital Procurement ##### 8.5.2 Retail Pharmacies ##### 8.5.3 Specialist Medical Distributors ##### 8.5.4 Digital Pharmacy and Direct-to-Consumer #### 8.6 Technology ##### 8.6.1 Conventional Electrochemical Monitoring ##### 8.6.2 Flash Glucose Monitoring ##### 8.6.3 Real-Time Continuous Glucose Monitoring ##### 8.6.4 Automated Insulin Delivery #### 8.7 Geography ##### 8.7.1 Muscat ##### 8.7.2 North Al Batinah ##### 8.7.3 Dhofar ##### 8.7.4 Interior and Other Governorates ### 9. Oman Diabetes Devices Market Competitive Analysis #### 9.1 Market Share of Key Players #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size ##### 9.2.3 Installed Patient Base ##### 9.2.4 Sensor Replacement Adherence ##### 9.2.5 Oman Diabetes Device Revenue Growth ##### 9.2.6 Gross Margin #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 Abbott Diabetes Care ##### 9.5.2 Roche Diabetes Care ##### 9.5.3 LifeScan ##### 9.5.4 Medtronic plc ##### 9.5.5 Ascensia Diabetes Care ##### 9.5.6 Dexcom, Inc. ##### 9.5.7 Insulet Corporation ##### 9.5.8 Ypsomed Holding AG ##### 9.5.9 ARKRAY, Inc. ##### 9.5.10 Becton, Dickinson and Company ### 10. Oman Diabetes Devices Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 Public Hospital Tender Cycles ##### 10.1.2 Specialist Clinic Prescribing Preferences ##### 10.1.3 Pharmacy Replenishment Decisions ##### 10.1.4 Homecare Brand Switching #### 10.2 Corporate Spend Patterns ##### 10.2.1 Meter Placement and Strip Pull-Through ##### 10.2.2 CGM Sensor Subscription Spending ##### 10.2.3 Pump Consumable Replacement Costs ##### 10.2.4 Patient Education and Support Spend #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Advanced Device Affordability ##### 10.3.2 Consumable Stock Continuity ##### 10.3.3 Data Interoperability Gaps ##### 10.3.4 Training and Adherence Burden #### 10.4 User Readiness for Adoption ##### 10.4.1 Smartphone Access and Digital Literacy ##### 10.4.2 Clinician Confidence in CGM Data ##### 10.4.3 Patient Willingness to Wear Sensors ##### 10.4.4 Caregiver Readiness for Remote Alerts #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Reduced Hypoglycemia Risk ##### 10.5.2 Fewer Unscheduled Care Encounters ##### 10.5.3 Improved Treatment Adjustment ##### 10.5.4 Expansion into High-Risk Monitoring ### 11. Oman Diabetes Devices Market Future Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Affordable CGM Subscription Whitespace #### 1.2 Primary-Care Starter Kit Model #### 1.3 Connected Clinic Dashboard Services #### 1.4 Rural Replenishment and Education Model ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Outcomes Positioning #### 2.2 Total Cost of Care Messaging #### 2.3 Patient Convenience and Adherence #### 2.4 Regulatory Compliance Differentiation ### 3. Distribution Plan #### 3.1 Authorized Medical Distributor Network #### 3.2 Hospital Tender Coverage #### 3.3 Retail Pharmacy Replenishment #### 3.4 Digital Pharmacy Subscription Fulfillment ### 4. Channel and Pricing Gaps #### 4.1 Public Tender Price Compression #### 4.2 Premium Sensor Affordability Gap #### 4.3 Peripheral Governorate Availability #### 4.4 Consumable Bundle Transparency ### 5. Unmet Demand and Latent Needs #### 5.1 Underdiagnosed Adult Monitoring Need #### 5.2 Pediatric Continuous Monitoring #### 5.3 Gestational Diabetes Support #### 5.4 Remote Clinician Review ### 6. Customer Relationship #### 6.1 Patient Onboarding Programs #### 6.2 Consumable Reorder Reminders #### 6.3 Clinician Training Partnerships #### 6.4 Adherence and Outcomes Support ### 7. Value Proposition #### 7.1 Reliable Device and Consumable Access #### 7.2 Lower Monitoring Burden #### 7.3 Actionable Glucose Data #### 7.4 Integrated Clinical Support ### 8. Key Activities #### 8.1 Product Registration and Vigilance #### 8.2 Tender and Formulary Engagement #### 8.3 Distributor Inventory Planning #### 8.4 Patient and Clinician Education ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Select Authorized Local Agent ##### 9.1.2 Register Manufacturer and Devices ##### 9.1.3 Secure Specialist Clinic Pilots ##### 9.1.4 Scale Pharmacy Replenishment #### 9.2 Export Entry Strategy ##### 9.2.1 Use Oman as GCC Reference Market ##### 9.2.2 Align Regional Product Registrations ##### 9.2.3 Consolidate Gulf Inventory Planning ##### 9.2.4 Build Cross-Border Clinical Evidence ### 10. Entry Mode Assessment #### 10.1 Exclusive Distributor Model #### 10.2 Multi-Channel Distributor Model #### 10.3 Direct Hospital Contracting #### 10.4 Digital Subscription Partnership ### 11. Capital and Timeline Estimation #### 11.1 Regulatory and Registration Budget #### 11.2 Launch Inventory Investment #### 11.3 Clinical Education Resources #### 11.4 Working Capital Requirements ### 12. Control vs Risk Trade-Off #### 12.1 Distributor Control and Coverage #### 12.2 Inventory Ownership Risk #### 12.3 Tender Concentration Exposure #### 12.4 Data Governance Responsibility ### 13. Profitability Outlook #### 13.1 Consumable Gross Margin #### 13.2 Sensor Subscription Economics #### 13.3 Service Revenue Attachment #### 13.4 Tender Discount Sensitivity ### 14. Potential Partner List #### 14.1 Authorized Medical-Device Distributors #### 14.2 Hospital and Clinic Networks #### 14.3 National Pharmacy Chains #### 14.4 Digital Health Platforms ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Complete Regulatory Registration ##### 15.2.2 Launch Specialist Clinic Pilots ##### 15.2.3 Expand Pharmacy Availability ##### 15.2.4 Introduce Connected Care Services ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage, Priority Metros and Secondary Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 - Hospitals and Specialist Clinics ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample and Muscat Coverage #### 3.2 Cohort 2 - Pharmacies and Medical Distributors ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample and Governorate Coverage #### 3.3 Cohort 3 - Insulin-Treated Home Users ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample and City Distribution #### 3.4 Cohort 4 - Caregivers and Pediatric Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 Health Expenditure and Chronic-Care Linkages ##### 4.1.2 Population and Obesity Impact ##### 4.1.3 Public Procurement Cycles and Timing ##### 4.1.4 Import Dependency on Diabetes Devices #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Testing Frequency and Consumable Volumes ##### 4.2.2 Treatment-Intensity Variations ##### 4.2.3 Brand Loyalty vs. Price Sensitivity ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Cohorts ##### 4.3.2 Price Benchmarking Against Conventional Monitoring ##### 4.3.3 Governorate Pricing and Availability Disparities ##### 4.3.4 Total Cost of Ownership Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Accuracy and Certification Requirements ##### 4.4.2 Device Safety and Vigilance Awareness ##### 4.4.3 Perception of Imported Device Brands ##### 4.4.4 After-Sales Service and Support Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Muscat and Governorate Demand Hotspots ##### 4.5.2 Family Caregiving and Monitoring Norms ##### 4.5.3 Clinician and Peer Influence ##### 4.5.4 Digital Adoption and E-Pharmacy Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Impact of Diabetes Awareness Campaigns ##### 4.6.2 Role of Digital Education Platforms ##### 4.6.3 Distributor and Pharmacy Influence ##### 4.6.4 Manufacturer and Clinical Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Gaps Between Device Access and User Expectations #### 5.2 Latent Demand in Underdiagnosed Adults #### 5.3 Willingness to Adopt Sensor Technologies #### 5.4 Pain Points Across Patient Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us